Semarang, 25th October 2022

To :

Editors

Journal of Biomedicine and Translational Research

Dear Dr./Mr./Ms. Managing Editor

I am writing to submit our manuscript entitled, “**INCREASED LEVEL OF THE PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 IS ASSOCIATED WITH SEVERITY OF NAFLD**” for consideration as an Original Article in. We explored the relationship between NAFLD as an independent factor for increasing PAI-1 in the presence of metabolic syndrome and insulin resistance. Our result suggest that PAI-1 levels have an independent effect on the degree of liver fibrosis in patients with NAFLD.

Although there were various studies have attempted to evaluate the role of PAI-1 in the pathogenesis of NAFLD, but they demonstrated conflicting results, we believe that the findings presented in our paper may provide useful information for the internist, gastrologist and even general practitioner. We think that this research will be interest the reader of your journal.

 This article represents our original work and we take full responsibility for the information provided. We declare that this article is not currently under consideration in another journal. It also has not presented in congress. All the co-author have seen and approved the manuscript as well as the order of authors. We also have no conflict of interest associated with this publication, and there has been no significant financial support for this work that would influenced its outcomes.

 We are looking forward for your consideration and hope this article could be published in your journal. Please let us know if this manuscript need any revision.

Sincerely yours,

dr. Didik Indiarso, Sp.PD, K-GEH

*Corresponding Author :*

*Hery Djagat Purnomo, MD, PhD*

*Divison of Gastroenterohepatology*

*Departement of Internal Medicine,*

*Medical Faculty , Diponegoro University*

*Semarang, Indonesia*

*Email address: herydjagat@yahoo.co.id*